Veradermics, Incorporated AI Stock Analysis
Want to see MANE full AI Analyst Report?
Veradermics, Incorporated (MANE) AI Stock Analysis
Veradermics, Incorporated
(NYSE:MANE)
The score is constrained primarily by weak financial fundamentals (no revenue, rapidly accelerating losses/cash burn, and a shift to deeply negative equity), which heighten financing risk. Offsetting this, recent clinical-trial corporate events are strongly positive and the technical picture is moderately constructive, while valuation remains challenged due to losses and no dividend support.
Veradermics, Incorporated (MANE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.47B
- Dividend Yield
- ―
- Average Volume (3M)
- 755.78K
- Price to Earnings (P/E)
- -49.1
- Beta (1Y)
- 0.19
- Revenue Growth
- ―
- EPS Growth
- -57.61%
- Country
- US
- Employees
- 51
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Veradermics, Incorporated Business Overview & Revenue Model
Company Description
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL)...
Veradermics, Incorporated Financial Statement Overview
Summary
Pre-revenue profile with sharply worsening losses and cash burn (net loss ~-$70.0M and operating cash flow ~-$71.6M in 2025). While assets increased and debt is minimal, the swing to deeply negative equity (~-$121.0M in 2025) materially raises funding and balance-sheet risk.
Income Statement
8Very NegativeBalance Sheet
22NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| EBITDA | -99.10M | -70.00M | -25.90M | -16.45M |
| Net Income | -93.58M | -70.00M | -26.49M | -16.49M |
Balance Sheet | ||||
| Total Assets | 807.22M | 152.62M | 59.38M | 18.46M |
| Cash, Cash Equivalents and Short-Term Investments | 798.35M | 141.86M | 53.08M | 16.30M |
| Total Debt | 668.00K | 4,000 | 0 | 786.00K |
| Total Liabilities | 10.74M | 273.63M | 4.72M | 3.84M |
| Stockholders Equity | 796.47M | -121.01M | 54.66M | 14.62M |
Cash Flow | ||||
| Free Cash Flow | -82.60M | -71.63M | -23.69M | -13.51M |
| Operating Cash Flow | -82.23M | -71.60M | -23.69M | -13.51M |
| Investing Cash Flow | -653.92M | -118.86M | 0 | 0 |
| Financing Cash Flow | 862.65M | 159.14M | 60.48M | 13.89M |
Veradermics, Incorporated Risk Analysis
Veradermics, Incorporated disclosed 83 risk factors in its most recent earnings report. Veradermics, Incorporated reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksVeradermics, Incorporated Peers Comparison
Overall Rating
KNSA80Outperform
ARQT79Outperform
CAI70Outperform
VCEL70Outperform
VCYT70Outperform
MANE54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | $7.57B | 67.36 | 17.27% | ― | 58.19% | 192.34% | |
| 79Outperform | $3.57B | 121.44 | 14.18% | ― | 60.00% | ― | |
| 70Outperform | $6.61B | 68.59 | 16.00% | ― | 61.48% | ― | |
| 70Outperform | $2.91B | 86.30 | 9.09% | ― | 25.30% | 147.62% | |
| 70Outperform | $1.96B | 15.30 | 9.27% | ― | 17.50% | 311.25% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | $5.47B | -49.11 | -19.90% | ― | ― | -57.61% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MANE | Veradermics, Incorporated | 129.66 | 91.91 | 243.47% | |
| VCEL | Vericel Corporation | 56.96 | 17.53 | 44.46% | |
| VCYT | Veracyte Inc | 24.33 | -14.95 | -38.06% | |
| KNSA | Kiniksa Pharmaceuticals Ltd. Class A | 96.33 | 54.93 | 132.68% | |
| ARQT | Arcutis Biotherapeutics Inc | 28.26 | 2.09 | 7.99% | |
| CAI | Caris Life Sciences, Inc. | 23.04 | -0.67 | -2.83% |
Veradermics, Incorporated Corporate Events
Veradermics Reports Positive Phase 2/3 Hair Loss Trial Results
PositiveOn November 9, 2026, Veradermics reported positive topline results from Part B of Study ‘302,’ a randomized Phase 2/3 trial of VDPHL01 in 519 men with mild-to-moderate pattern hair loss. After six months, placebo participants switched to VDPHL01 for...
Veradermics Reports Strong Phase 3 Hair Loss Results
PositiveOn October 19, 2026, Veradermics reported positive topline results from its Phase 3 Study ‘304’, a multi-center, randomized, placebo-controlled trial of oral VDPHL01 in 536 men with mild-to-moderate pattern hair loss. The extended-release minoxidil p...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
